瑞卢戈利心血管安全风险信号的挖掘与评价

林永春; 蒙龙; 郑佳峻; 蒋慧明

doi:10.6039/j.issn.1001-0408.2024.18.15

您当前的位置：

首页 >

文章列表页 >

瑞卢戈利心血管安全风险信号的挖掘与评价

药物与临床 | 更新时间：2024-09-25

- 瑞卢戈利心血管安全风险信号的挖掘与评价
- Mining and evaluation of relugolix-related cardiovascular safety signals
- 中国药房 2024年35卷第18期页码：2278-2282
- 作者机构：
  
  1.湛江中心人民医院临床药学科，广东湛江　524037
  2.重庆医科大学附属第一医院药学部，重庆　400016
  3.重庆大学大数据与软件学院，重庆　401331
- 作者简介：
  
  主管药师。研究方向：临床药学。E-mail：13434689122@139.com
  主管药师，硕士。研究方向：临床药学、医院药学。 E-mail：3942020@qq.com
- 基金信息：
  
  重庆市科卫联合医学科研项目(2023QNXM039)
- DOI：10.6039/j.issn.1001-0408.2024.18.15
  中图分类号： R969.3
- 纸质出版日期：2024-09-30，
  
  收稿日期：2024-04-10，
  
  修回日期：2024-08-22，
- 稿件说明：
移动端阅览
林永春,蒙龙,郑佳峻等.瑞卢戈利心血管安全风险信号的挖掘与评价 ^Δ[J].中国药房,2024,35(18):2278-2282.

LIN Yongchun,MENG Long,ZHENG Jiajun,et al.Mining and evaluation of relugolix-related cardiovascular safety signals[J].ZHONGGUO YAOFANG,2024,35(18):2278-2282.
林永春,蒙龙,郑佳峻等.瑞卢戈利心血管安全风险信号的挖掘与评价 ^Δ[J].中国药房,2024,35(18):2278-2282. DOI： 10.6039/j.issn.1001-0408.2024.18.15.

LIN Yongchun,MENG Long,ZHENG Jiajun,et al.Mining and evaluation of relugolix-related cardiovascular safety signals[J].ZHONGGUO YAOFANG,2024,35(18):2278-2282. DOI： 10.6039/j.issn.1001-0408.2024.18.15.

摘要

目的

挖掘瑞卢戈利的心血管安全风险信号，为该药在我国上市及未来的临床安全用药评估提供参考。

方法

收集美国FDA不良事件报告系统（FAERS）中2021年第1季度至2023年第3季度以瑞卢戈利为主要/次要怀疑药物的不良事件（AE）报告，采用报告比值比（ROR）法进行数据挖掘。利用《国际医学用语词典》（MedDRA）24.0版中的首选术语（PT）对药物AE名称进行编码；采用狭义标准MedDRA查询（SMQ）术语和高位语（HLT）术语定义和分析目标AE。分别通过以瑞卢戈利为主要/次要怀疑药物或与药物相互作用、伴随使用药物有关的AE和广义SMQ术语进行敏感性分析。

结果

共得到瑞卢戈利AE报告4 354份。得到狭义SMQ术语9个，含异常血脂症、高血糖症/新发糖尿病2个阳性信号；得到HLT术语11个，含胆固醇各项分析、甘油三酯分析和各种高血糖状况（不另分类）3个阳性信号。敏感性分析结果显示，上述研究结果可靠。

结论

瑞卢戈利存在高血脂和高血糖风险信号，但未发现高血压、心脏病和脑卒中等风险信号。临床在使用瑞卢戈利时，需关注患者的高血脂、高血糖AE。

Abstract

OBJECTIVE

To mine the cardiovascular safety signal of relugolix， and provide a reference for the listing of this drug in China and future clinical safety drug evaluation.

METHODS

The adverse event （AE） report data of relugolix， as the primary or secondary suspected drug， was collected from the FDA Adverse Event Reporting System （FAERS） from the first quarter of 2021 to the third quarter of 2023. The reporting odds ratio （ROR） method was used for data mining. The AEs in the FAERS database were identified and coded using preferred terms （PT） stated in version 24.0 of the

Medical Dictionary for Drug Regulatory Activities

（MedDRA）. The AEs of the target drug were identified by the narrow standardized MedDRA query （SMQ） terms and high-level term （HLT）. Sensitivity analysis was conducted using AEs suspected to be primarily or secondarily related to relugolix or related to drug interaction and concomitant drug， and broad SMQ terms.

RESULTS

A total of 4 354 relugolix-related AE reports were extracted. In the primary analysis， nine SMQ terms were analyzed， involving 2 positive signals such as dyslipidemia and hyperglycemia/new onset diabetes mellitus. Eleven HLTs were analyzed， and three positive signals were detected for three terms including cholesterol analyses， triglyceride analyses and hyperglycemia conditions （non-alternative analysis）. Sensitivity analysis results indicated the reliability of the study findings.

CONCLUSIONS

Relugolix may induce risk signals related to high blood lipids and high blood glucose， but no moderate risk signals such as hypertension， heart disease， and stroke are found. During relugolix treatment in clinical practice， attention must be paid to hyperlipidemia and hyperglycemia-related AE.

关键词

瑞卢戈利促性腺激素释放激素拮抗剂不良事件心血管事件高血脂高血糖

Keywords

gonadotropin-releasing hormone antagonistadverse eventcardiovascular eventhyperlipidemiahyperglycemia

references

KIM D K，LEE H S，PARK J Y，et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study[J]. J Cancer Res Clin Oncol，2021，147（4）：1217-1226.

STURGEON K M，DENG L，BLUETHMANN S M，et al. A population-based study of cardiovascular disease mortality risk in US cancer patients[J]. Eur Heart J，2019，40（48）：3889-3897.

GEORGE G，GARMO H，SCAILTEUX L M，et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer：real-world evidence from five databases[J]. Int J Cancer，2021，148（9）：2203-2211.

SHORE N D，SAAD F，COOKSON M S，et al. Oral relugolix for androgen-deprivation therapy in advanced pro-state cancer[J]. N Engl J Med，2020，382（23）：2187-2196.

SUN Y H，XIE L P，XU T，et al. Efficacy and safety of degarelix in patients with prostate cancer：results from a phase Ⅲ study in China[J]. Asian J Urol，2020，7（3）：301-308.

AXCRONA K，AALTOMAA S，DA SILVA C M，et al. Androgen deprivation therapy for volume reduction，lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer：degarelix vs goserelin plus bicalutamide[J]. BJU Int，2012，110（11）：1721-1728.

陈本川. 靶向激素依赖性失衡所致晚期前列腺癌治疗新药：瑞卢戈利（relugolix）[J]. 医药导报，2021，40（7）：984-990，

Ⅰ.

CHEN B C. Relugolix，a new drug for the treatment of advanced prostate cancer caused by hormone-dependent imbalance[J]. Her Med，2021，40（7）：984-990，Ⅰ.

何家汝，卢伟涛，黄雅焱，等. 基于FAERS数据库的特立帕肽与阿巴洛肽不良事件信号挖掘[J]. 中国现代应用药学，2023，40（7）：956-963.

HE J R，LU W T，HUANG Y Y，et al. Adverse drug events signal mining of teriparatide and abaloparatide based on FAERS database[J]. Chin J Mod Appl Pharm，2023，40（7）：956-963.

PEARSON R K，HAUBEN M，GOLDSMITH D I，et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results[J]. Int J Med Inform，2009，78（12）：e97-e103.

HUANG J，ZHAO Y B，CAO Y N，et al. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction，perforation，and ulceration：an analysis of the FDA Adverse Event Reporting System database（FAERS）[J]. Int J Clin Pharm，2022，44（4）：993-1003.

彭媛，王程程，唐利，等. 西格列汀上市后致皮肤不良反应的信号挖掘与评价[J]. 中国药房，2014，25（2）：156-158.

PENG Y，WANG C C，TANG L，et al. Signal excavation and evaluation of sitagliptin induced skin ADR after going public[J]. China Pharm，2014，25（2）：156-158.

PERRONE V，DEGLI ESPOSTI L，GIACOMINI E，et al. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists：an Italian real-world analysis[J]. Ther Clin Risk Manag，2020，16：393-401.

ALBERTSEN P C，KLOTZ L，TOMBAL B，et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist[J]. Eur Urol，2014，65（3）：565-573.

ELAGIZI A，KÖHLER T S，LAVIE C J. Testosterone and cardiovascular health[J]. Mayo Clin Proc，2018，93（1）：83-100.

徐涛，韩敬丽，姚伟娟. 雄激素剥夺治疗相关心血管疾病的机制与临床对策[J]. 北京大学学报（医学版），2020，52（4）：607-609.

XU T，HAN J L，YAO W J. Mechanism and clinical countermeasures of androgen deprivation in the treatment of cardiovascular diseases[J]. J Peking Univ Health Sci，2020，52（4）：607-609.

WANG Q，ZHOU J，YAO W，et al. 54-Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation[J]. Eur Urol Suppl，2019，18（1）：e72.

CRAWFORD E D，TOMBAL B，MILLER K，et al. A phase Ⅲ extension trial with a 1-arm crossover from leu-prolide to degarelix：comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer[J]. J Urol，2011，186（3）：889-897.

MEIROW D，ASSAD G，DOR J，et al. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice[J]. Hum Reprod，2004，19（6）：1294-1299.

KNUTSSON A，HSIUNG S，CELIK S，et al. Treatment with a GnRH receptor agonist，but not the GnRH receptor antagonist degarelix，induces atherosclerotic plaque instability in ApoE－/－ mice[J]. Sci Rep，2016，6：26220.

ARJONA FERREIRA J C，MIGOYA E. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis[J]. F S Rep，2022，4（Suppl. 2）：73-82.

FRADIN J，KIM F J，LU-YAO G L，et al. Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer[J]. Cancers，2023，15（8）：2316.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

药源性糖代谢紊乱的研究进展

格列齐特在糖尿病肾病治疗中带来肾获益的研究进展